4130. Covid-19 Surveillance Testing and Resident Outcomes in Nursing Homes.
Despite widespread adoption of surveillance testing for coronavirus disease 2019 (Covid-19) among staff members in skilled nursing facilities, evidence is limited regarding its relationship with outcomes among facility residents.
4131. Acute Effects of Coffee Consumption on Health among Ambulatory Adults.
作者: Gregory M Marcus.;David G Rosenthal.;Gregory Nah.;Eric Vittinghoff.;Christina Fang.;Kelsey Ogomori.;Sean Joyce.;Defne Yilmaz.;Vivian Yang.;Tara Kessedjian.;Emily Wilson.;Michelle Yang.;Kathleen Chang.;Grace Wall.;Jeffrey E Olgin.
来源: N Engl J Med. 2023年388卷12期1092-1100页
Coffee is one of the most commonly consumed beverages in the world, but the acute health effects of coffee consumption remain uncertain.
4134. SARS-CoV-2 Variants and Multisystem Inflammatory Syndrome in Children.
作者: Brian W McCrindle.;Ashraf S Harahsheh.;Ryan Handoko.;Geetha Raghuveer.;Michael A Portman.;Michael Khoury.;Jane W Newburger.;Simon Lee.;Supriya S Jain.;Manaswitha Khare.;Nagib Dahdah.;Cedric Manlhiot.; .
来源: N Engl J Med. 2023年388卷17期1624-1626页 4135. Hydrocortisone in Severe Community-Acquired Pneumonia.
作者: Pierre-François Dequin.;Ferhat Meziani.;Jean-Pierre Quenot.;Toufik Kamel.;Jean-Damien Ricard.;Julio Badie.;Jean Reignier.;Nicholas Heming.;Gaëtan Plantefève.;Bertrand Souweine.;Guillaume Voiriot.;Gwenhaël Colin.;Jean-Pierre Frat.;Jean-Paul Mira.;Nicolas Barbarot.;Bruno François.;Guillaume Louis.;Sébastien Gibot.;Christophe Guitton.;Christophe Giacardi.;Sami Hraiech.;Sylvie Vimeux.;Erwan L'Her.;Henri Faure.;Jean-Etienne Herbrecht.;Camille Bouisse.;Aurélie Joret.;Nicolas Terzi.;Arnaud Gacouin.;Charlotte Quentin.;Mercé Jourdain.;Marie Leclerc.;Carine Coffre.;Hélène Bourgoin.;Céline Lengellé.;Caroline Caille-Fénérol.;Bruno Giraudeau.;Amélie Le Gouge.; .
来源: N Engl J Med. 2023年388卷21期1931-1941页
Whether the antiinflammatory and immunomodulatory effects of glucocorticoids may decrease mortality among patients with severe community-acquired pneumonia is unclear.
4139. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
作者: Jonathan I Silverberg.;Emma Guttman-Yassky.;Diamant Thaçi.;Alan D Irvine.;Linda Stein Gold.;Andrew Blauvelt.;Eric L Simpson.;Chia-Yu Chu.;Zhuqing Liu.;Renata Gontijo Lima.;Sreekumar G Pillai.;Julien Seneschal.; .
来源: N Engl J Med. 2023年388卷12期1080-1091页
Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα-interleukin-13Rα1 heterodimer receptor signaling complex.
|